Leronlimab

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameLeronlimab
Drug Alias NameVyrologixPA-14PRO-140HuPRO-140
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionC-C chemokine receptor type 5 antagonists
TargetsC-C chemokine receptor type 5
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursCognitive Dysfunction +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoBrazil
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesProgenics Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell UniversityRegnum CorpSevenScore Pharmaceuticals LLC +[5] 
Inactive CompaniesDrexel University
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursCognitive Dysfunction +[6] 
Inactive IndicationsGraft vs Host DiseaseColorectal NeoplasmsTriple Negative Breast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG